UniProt Q13873 · PDB · AlphaFold · Substrate: MBP · Clone: Catalytic (aa174-end)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Defactinib | 83.5% | 16.5% | 92.68 | 0.450 |
| 2 | Deucravacitinib | 60.8% | 39.2% | 98.99 | 0.718 |
| 3 | Abemaciclib | 54.8% | 45.2% | 91.48 | 0.563 |
| 4 | Sunitinib | 52.8% | 47.2% | 91.73 | 0.524 |
| 5 | Bosutinib | 43.1% | 56.9% | 87.22 | 0.555 |
| 6 | Palbociclib | 42.3% | 57.7% | 98.75 | 0.673 |
| 7 | Gilteritinib | 41.0% | 59.0% | 88.97 | 0.506 |
| 8 | Ponatinib | 40.2% | 59.8% | 78.23 | 0.534 |
| 9 | Pacritinib | 36.3% | 63.7% | 88.64 | 0.452 |
| 10 | Alectinib | 36.2% | 63.8% | 95.49 | 0.651 |
| 11 | Avapritinib | 35.8% | 64.2% | 97.73 | 0.644 |
| 12 | Abrocitinib | 35.8% | 64.2% | 99.50 | 0.581 |
| 13 | Crizotinib | 35.6% | 64.4% | 91.39 | 0.581 |
| 14 | Selpercatinib | 34.0% | 66.0% | 96.72 | 0.635 |
| 15 | Midostaurin | 31.9% | 68.1% | 78.64 | 0.500 |
| 16 | Dabrafenib | 29.8% | 70.2% | 94.74 | 0.633 |
| 17 | Tepotinib | 25.1% | 74.9% | 99.75 | 0.727 |
| 18 | Ruxolitinib | 25.0% | 75.0% | 98.25 | 0.592 |
| 19 | Afatinib | 24.7% | 75.3% | 98.50 | 0.709 |
| 20 | Nintedanib | 23.4% | 76.6% | 90.23 | 0.608 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.24
- Epithelial log2(TPM+1): 3.14
- Fold change: 1.10
- Status: Upregulated
Selectivity landscape vs inhibition on BMPR2
Each point is one of the 92 approved drugs; color = inhibition % on BMPR2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…